News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Markets mostly unchanged as no major headlines emerged in the past hour.
  • US equities traded with low volatility and light volume across sectors.
  • Treasury yields moved little, reflecting muted risk sentiment and no fresh economic data.
  • Dollar held steady against majors amid absence of new monetary guidance.
  • Oil and commodities showed minimal movement without supply or demand shocks.
  • No significant geopolitical or corporate announcements were reported in the last hour.

Latest Articles

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, a clinical-stage oncology firm focusing on RAS-addicted cancer therapies, announced an increase in its concurrent public offerings to raise approximately $2 billion. The offerings include about 10.56 million shares of common stock priced at $142 per share (up from $750 million to $1.5 billion) and $500 million in 0.5% converti…

Progressive Reports March 2026 Results

Progressive Reports March 2026 Results

The Progressive Corporation reported solid financial results for March 2026 and the first quarter, showing growth in net premiums written by 10% for the month and 6% for the quarter. Net income increased by 36% in March and 10% for the quarter compared to the previous year. The combined ratio improved slightly for the month but was flat for the qua…

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL, Inc. has rescheduled its shareholder update conference call to April 23, 2026 to provide updates on its potential transaction with Celularity Inc. The company announced it will not finance the transaction under its previous agreement and is negotiating a new financing structure with another investor group. Details on the transaction and fin…

T3 Defense Announces Unaudited Preliminary Key Financial and Operational Metrics for Q1 2026, Its First Reporting Quarter as a Defense-Focused Holding Company

T3 Defense Announces Unaudited Preliminary Key Financial and Operational Metrics for Q1 2026, Its First Reporting Quarter as a Defense-Focused Holding Company

T3 Defense Inc. announced its unaudited preliminary financial and operational results for Q1 2026, the company's first full quarter operating as a defense-focused holding company. The company expects Q1 revenue of approximately $4.2 million and confirms its full-year 2026 revenue guidance of $26 million, supported by a robust backlog of over $12 mi…

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences announced the successful transfer of cytisinicline manufacturing technology to US-based Adare Pharma Solutions, including completion of analytical method transfer and production of the first engineering batch. Despite previous FDA cGMP inspection concerns at the former facility, Achieve plans to resubmit its NDA with Adare as …

Reviva Announces Letter to Shareholders

Reviva Announces Letter to Shareholders

Reviva Pharmaceuticals provided an update to shareholders detailing its recent $10 million financing to strengthen cash reserves, plans to extend the patent life of its lead drug candidate brilaroxazine through a new formulation, and preparations to initiate a second Phase 3 schizophrenia trial (RECOVER-2). The company seeks FDA alignment on the ne…

Texas Wealth Solutions Joins LPL’s Independent Advisor Network

Texas Wealth Solutions Joins LPL’s Independent Advisor Network

LPL Financial announced that Brian Bogue has launched Texas Wealth Solutions by affiliating with LPL's Independent Advisor Network. Bogue brings approximately $235 million in assets under management and over 25 years of experience, focusing on serving pre-retirees and retirees in East Texas. This move enables him to operate independently while leve…

Carriage Services Declares Quarterly Cash Dividend

Carriage Services Declares Quarterly Cash Dividend

Carriage Services, Inc., a US-based provider of funeral and cemetery services, announced a quarterly cash dividend of 11.25 cents per share, payable June 1, 2026, to shareholders of record May 4, 2026. The company operates 155 funeral homes and 28 cemeteries across multiple states, emphasizing innovation and elevated service.

DSS, Inc. Letter to Shareholders

DSS, Inc. Letter to Shareholders

DSS, Inc. announces substantial operational progress in 2025, including a 43% reduction in costs and expenses, enhanced financial discipline, and strategic realignment into four core business segments. The company highlights growth in Product Packaging and Securities & Investment Management, completed the spin-out of Impact BioMedical, and plans a …

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

PDS Biotechnology announced encouraging interim Phase 2 clinical trial results for its tumor-targeted IL-12 immunocytokine, PDS01ADC, in patients with metastatic colorectal cancer (mCRC) with liver metastases. The trial showed a 78% objective response rate and over 80% two-year survival, significantly outperforming parallel studies without PDS01ADC…

XMax Inc. Announces Fiscal Year 2025 Financial Results

XMax Inc. Announces Fiscal Year 2025 Financial Results

XMax Inc. announced a 73% increase in net sales for fiscal year 2025, driven by its furniture business, while also embarking on a new strategic expansion into artificial intelligence technologies. The company established a subsidiary, XMax AI Inc., and partnered to build a cloud-based AI platform on AWS, signaling diversification of revenue streams…

Allbirds, Inc. Executes $50M Convertible Financing Facility Agreement; Announces Expansion into AI Compute Infrastructure

Allbirds, Inc. Executes $50M Convertible Financing Facility Agreement; Announces Expansion into AI Compute Infrastructure

Allbirds, Inc. announced a $50 million convertible financing facility to fund its strategic pivot from footwear to AI compute infrastructure. Following the sale of its brand and footwear assets to American Exchange Group, the company plans to become NewBird AI, a GPU-as-a-Service and AI-native cloud provider targeting the unmet demand for high-perf…